Decreased Expression of MicroRNA-214 Contributes to Imatinib Mesylate Resistance of Chronic Myeloid Leukemia Patients by Upregulating ABCB1 Gene Expression

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2018 Sep 7

PMID 30186389

Citations 8

Authors

Jing Jin

Jia Yao

Fang Yue

Zhaoying Jin

Dan Li

Shan Wang

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to determine the expression of adenosine triphosphate binding cassette subfamily B member 1 (ABCB1) gene and its protein P-glycoprotein (PGP) in bone marrow mononuclear cells from chronic myeloid leukemia (CML) patients with imatinib mesylate (IM) resistance, or IM-resistant CML K562 cells. In addition, the molecular mechanism of action of microRNA (miR)-214 on ABCB1 in IM resistance was investigated. A total of 26 CML patients with IM resistance were included in the present study. In addition, 31 CML patients who did not have IM resistance were included as the control group. Bone marrow was collected from all subjects. The K562R cell line, which is a K562 cell line with IM resistance, was used for cellular studies. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression of ABCB1 mRNA and miR-214 in cells. Western blotting was employed to determine the expression of PGP. Dual luciferase reporter assay was carried out to identify interactions between ABCB1 mRNA and miR-214. MTT assay was used to determine the survival rate of cells. ABCB1 mRNA and PGP expression was upregulated in bone marrow mononuclear cells from CML patients with IM resistance. K562R cells had higher ABCB1 and PGP expression than K562 cells, potentially due to their different sensitivity to IM. Expression miR-214 was decreased in bone marrow mononuclear cells from patients with IM resistance and K562R cells. Notably, miR-214 was able to bind with the 3'-untranslated region, seed region of ABCB1 mRNA to regulate its expression. In addition, elevated expression of miR-214 restored IM sensitivity to K562R cells potentially by affecting ABCB1 expression. The present study demonstrated that upregulated expression of ABCB1 mRNA and PGP in bone marrow mononuclear cells from CML patients with IM resistance may be associated with the downregulation of miR-214. In addition, miR-214 may participate in the IM resistance of CML patients by regulating ABCB1 expression.

Citing Articles

Dynamic Roles of RNA and RNA Epigenetics in HTLV-1 Biology.

King E, Panfil A Viruses. 2025; 17(1).

PMID: 39861913 PMC: 11769288. DOI: 10.3390/v17010124.

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.

Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways.

Rahmati A, Mafi A, Vakili O, Soleymani F, Alishahi Z, Yahyazadeh S Ann Hematol. 2023; 103(5):1455-1482.

PMID: 37526673 DOI: 10.1007/s00277-023-05383-3.

The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia.

Ghazimoradi M, Karimpour-Fard N, Babashah S Genes (Basel). 2023; 14(1).

PMID: 36672872 PMC: 9859176. DOI: 10.3390/genes14010131.

Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance.

Rudich A, Garzon R, Dorrance A Int J Mol Sci. 2022; 23(20).

PMID: 36293127 PMC: 9603161. DOI: 10.3390/ijms232012271.

References

Mahon F, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F . Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-35. DOI: 10.1016/S1470-2045(10)70233-3. View

Wan D, Zhang Z, Yang H . Cardioprotective effect of miR-214 in myocardial ischemic postconditioning by down-regulation of hypoxia inducible factor 1, alpha subunit inhibitor. Cell Mol Biol (Noisy-le-grand). 2015; 61(2):1-6. View

Shah N . Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005; :183-7. DOI: 10.1182/asheducation-2005.1.183. View

Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H . MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One. 2015; 10(2):e0118086. PMC: 4338228. DOI: 10.1371/journal.pone.0118086. View

Inoue K . [MicroRNA function in animal development]. Tanpakushitsu Kakusan Koso. 2007; 52(3):197-204. View

Graziano A, Lo Monte G, Piva I, Caserta D, Karner M, Engl B . Diagnostic findings in adenomyosis: a pictorial review on the major concerns. Eur Rev Med Pharmacol Sci. 2015; 19(7):1146-54. View

Wang F, Lv P, Liu X, Zhu M, Qiu X . microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53. Int J Mol Med. 2015; 35(5):1395-402. DOI: 10.3892/ijmm.2015.2123. View

Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira R, Carvalho F, Bastos M . Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2014; 149:1-123. DOI: 10.1016/j.pharmthera.2014.11.013. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Mlejnek P, Kosztyu P, Dolezel P, Bates S, Ruzickova E . Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Chem Biol Interact. 2017; 273:171-179. DOI: 10.1016/j.cbi.2017.06.012. View

11.

Williams A, Moschos S, Perry M, Barnes P, Lindsay M . Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. Dev Dyn. 2006; 236(2):572-80. PMC: 2582151. DOI: 10.1002/dvdy.21047. View

12.

Silva K, de Souza P, Nestal de Moraes G, Moellmann-Coelho A, da Cunha Vasconcelos F, Maia R . XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res. 2013; 37(10):1350-8. DOI: 10.1016/j.leukres.2013.06.014. View

13.

Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A . Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005; 19(6):984-9. DOI: 10.1038/sj.leu.2403756. View

14.

Vine J, Cohen S, Ruchlemer R, Goldschmidt N, Levin M, Libster D . Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014; 55(11):2525-31. DOI: 10.3109/10428194.2014.893307. View

15.

Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M . Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013; 122(7):1284-92. PMC: 3744993. DOI: 10.1182/blood-2013-04-495598. View

16.

Hochhaus A, Hughes T . Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 2004; 18(3):641-56, ix. DOI: 10.1016/j.hoc.2004.03.001. View

17.

Lv Z, Fan Y, Chen H, Zhao D . Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour Biol. 2014; 36(3):1619-25. DOI: 10.1007/s13277-014-2760-9. View

18.

Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham M . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987; 84(21):7735-8. PMC: 299375. DOI: 10.1073/pnas.84.21.7735. View

19.

Zhou S . Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008; 38(7-8):802-32. DOI: 10.1080/00498250701867889. View

20.

Izawa T, Horiuchi T, Atarashi M, Kuwamura M, Yamate J . Anti-fibrotic Role of miR-214 in Thioacetamide-induced Liver Cirrhosis in Rats. Toxicol Pathol. 2015; 43(6):844-51. DOI: 10.1177/0192623315573587. View